XOMA Announces Encouraging Interim Results From Gevokizumab Phase 2 Study for Moderate to Severe Acne Vulgaris

[at noodls] – BERKELEY, Calif., Jan. 7, 2013 (GLOBE NEWSWIRE) — XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and development of therapeutic antibodies, today announced preliminary top-line data from an … more

View todays social media effects on XOMA

View the latest stocks trending across Twitter. Click to view dashboard

See who XOMA is hiring next, click here to view